ClinicalTrials.gg
Not yet recruitingNCT07483671Updated Mar 19, 2026

Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients

A Phase 2 interventional study of BPR-101 capsules:Investigational product for the treatment of BV and Placebo:matching the investigational product in appearance, dosage form, and route of administration in Bacterial Vaginosis, sponsored by Chengdu Syncor Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Chengdu Syncor Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Vaginosis, Bacterial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Vaginosis, Bacterial · China.

Planned enrollment
10th of 16
80 · median 123
Started
2026
with 2 others
Phase 2
4 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Chengdu Syncor Pharmaceutical Co., Ltd.

Among the 16 studies in Vaginosis, Bacterial with a site in China, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 in phase 2, and was the 14th registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

6 of the 16 studies in Vaginosis, Bacterial with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Vaginosis, Bacterial with a site in China, or all of them as a file.
02

Study summary

This trial employed a multicenter, randomized, double-blind, parallel, placebo-controlled design to evaluate the preventive effect of BPR-101 capsules combined with metronidazole on the recurrence of BV, as well as the cure rate and safety.

03

Conditions studied

  • Bacterial Vaginosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged ≥18 years and ≤50 years, of childbearing age with a history of sexual activity;
  2. Clinically diagnosed with Bacterial Vaginosis (BV), this test requires meeting at least 3 of the following 4 Amsel criteria (with a positive clue cell test being a mandatory condition): positive clue cells; positive amine test; vaginal discharge pH > 4.5; and Vaginal discharge is homogeneous, thin, and grayish-white in appearance;
  3. Nugent score ≥ 7 points;
  4. Vaginal administration is acceptable, and the patient agrees to avoid using any other vaginal products (such as creams, gels, foams, sponges, lubricants, douches, tampons, etc.) except as specified in the trial throughout the entire trial period;
  5. Researchers have assessed that the menstrual cycle is regular;
  6. Subjects must voluntarily sign a written form before the trial, understand the procedures and methods of the trial, and be willing to strictly abide by the clinical trial protocol and complete the trial.

Exclusion criteria

Exclusion Criteria:

  1. Currently suffering from pelvic inflammatory disease, acute cervicitis, and urinary tract infection requiring intervention, among other acute infections of the genitourinary system;
  2. Presence of vulvovaginitis caused by other pathogens, which researchers considered to affect trial evaluation, such as aerobic vaginitis (AV), vulvovaginal candidiasis (VVC), and trichomoniasis;
  3. Currently, other vaginal or vulvar diseases are considered by researchers to affect the evaluation of the trial, such as human papillomavirus infection; or gynecological examinations showing condyloma acuminata or genital herpes;
  4. Unexplained abnormal vaginal bleeding within 6 months prior to screening or during the screening visit;
  5. Those who currently have uterine fibroids, endometrial hyperplasia, endometriosis, or adenomyosis, and for whom researchers believe that intervention is necessary during the trial;
  6. Received local or systemic antifungal or antibiotic treatment or probiotic treatment within 2 weeks prior to screening; or vaginal douching or other vaginal treatments (such as Jieeryin, Jieyinkang, etc.) within 1 week prior to screening, and/or expected to receive the above treatments during the trial;
  7. Used systemic (oral or injectable), disulfiram, lithium salts within 14 days prior to screening., and/or expected to receive such treatment during the trial;
  8. Currently using and/or expected to require cimetidine, warfarin (or other anticoagulation therapy) during the trial;
  9. Products containing alcohol or propylene glycol that are expected to be used within 3 days prior to screening and/or during the trial period;
  10. Hhistory of malignant tumors within 5 years prior to screening and deemed unsuitable for inclusion by the researchers, except for those with adequately treated basal cell carcinoma or squamous cell carcinoma of the skin and cervical carcinoma in situ;
  11. Hhistory of major gynecological surgery within 6 months prior to screening(deep wounds, long recovery time), or superficial gynecological surgery or common procedures within 60 days prior to screening,or whose screening visit is within 60 days of their last termination of pregnancy;
  12. History of or currently suffering from serious diseases of the cardiovascular, liver, kidney, lung, digestive tract, nervous and mental system, genitourinary system, endocrine system, etc., and are deemed unsuitable for inclusion by the researchers;
  13. Laboratory tests meeting any of the following criteria, and the investigator deems them unsuitable for inclusion: serum creatinine > 1.5 times the (ULN); urea/urea nitrogen > 1.5 ULN; (ALT) > 2 ULN; aspartate aminotransferase (AST) > 2 ULN;
  14. Known to any component of BPR-101 capsules or to other similar drugs (such as Live Lactobacillus Capsule for Vaginal Use ); or nitroimidazole, metronidazole, or any of the ;
  15. Women who are pregnant or breastfeeding, or whose pregnancy test results are positive, or who plan to become pregnant throughout the trial and within 3 months after the last dose; or who cannot accept the use of reliable (absence of sexual intercourse or barrier contraception with condoms throughout the study period);
  16. Participated in other drug or device clinical trials within 1 month prior to screening and have used the drug or device;
  17. The researchers believe that the subject has any other circumstances that would make them unsuitable to participate in the trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Probiotic Group

    Capsules: Insert the capsule deep into the vagina. Metronidazole: Oral administration.

    Drug: BPR-101 capsules:Investigational product for the treatment of BV

  • Placebo comparator
    Control Group

    Capsules: Insert the capsule deep into the vagina. Metronidazole: Oral administration.

    Other: Placebo:matching the investigational product in appearance, dosage form, and route of administration

Interventions

  • DrugBPR-101 capsules:Investigational product for the treatment of BV

    administered vaginally and orally as per study protocol.

  • OtherPlacebo:matching the investigational product in appearance, dosage form, and route of administration

    administered vaginally and orally as per study protocol.

06

What researchers measure

Primary outcomes

  1. The recurrence rate of BV

    Nugent score + Amsel's test; any positive result indicates a relapse

    Time frame: Day 90

Secondary outcomes

  1. The recurrence rate of BV

    Time frame: Day 25 and 60

  2. The cure rate of BV

    Time frame: Day 15

  3. The recurrence rate of BV in cured patients

    Time frame: Day 90

  4. The time from the last dose of trial medication to the first recurrence of BV

    Time frame: From the last dose of medication in the trial to the first recurrence of BV

  5. Adverse events and serious adverse events, vital sign measurements, physical examination, gynecological examination, and laboratory test results (including blood/urine pregnancy test, complete blood count, blood biochemistry, and urinalysis).

    Time frame: Throughout the research period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jan 2027, 9 months later.

Of 14 phase 2 interventional studies under Vaginosis, Bacterial, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 19, 2026
StartEst.
Apr 15, 2026
Primary completionEst.
Jan 24, 2027
CompletionEst.
Jan 24, 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483671
Lead sponsor
Chengdu Syncor Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Jan 24, 2027 (estimated)
Completion
Jan 24, 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Ke Yao
Contact
ke.yao@btyy.com
028-85142721
FengXia Xue, Doctor of Medicine(M.D.)
principal investigator · Tianjin Medical University General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion